Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

The National Cancer Institute's PREVENT Cancer Preclinical Drug Development Program: overview, current projects, animal models, agent development strategies, and molecular targets.

Shoemaker RH, Suen CS, Holmes CA, Fay JR, Steele VE.

Semin Oncol. 2016 Feb;43(1):189-197. doi: 10.1053/j.seminoncol.2015.09.008. Epub 2015 Sep 8. Review.

2.

Energy homeostasis and cancer prevention: the AMP-activated protein kinase.

Fay JR, Steele V, Crowell JA.

Cancer Prev Res (Phila). 2009 Apr;2(4):301-9. doi: 10.1158/1940-6207.CAPR-08-0166. Epub 2009 Mar 31. Review.

3.

Targeting the AKT protein kinase for cancer chemoprevention.

Crowell JA, Steele VE, Fay JR.

Mol Cancer Ther. 2007 Aug;6(8):2139-48. Review.

4.

The mammalian target of rapamycin pathway as a potential target for cancer chemoprevention.

Kopelovich L, Fay JR, Sigman CC, Crowell JA.

Cancer Epidemiol Biomarkers Prev. 2007 Jul;16(7):1330-40. Review.

5.

Targeting epigenetic regulatory mechanisms in cancer chemoprevention.

Fay JR, Crowell JA, Kopelovich L.

Expert Opin Ther Targets. 2005 Apr;9(2):315-28. Review.

PMID:
15934918
6.

The epigenome as a target for cancer chemoprevention.

Kopelovich L, Crowell JA, Fay JR.

J Natl Cancer Inst. 2003 Dec 3;95(23):1747-57. Review.

PMID:
14652236
7.

Is inducible nitric oxide synthase a target for chemoprevention?

Crowell JA, Steele VE, Sigman CC, Fay JR.

Mol Cancer Ther. 2003 Aug;2(8):815-23. Review.

8.

Peroxisome proliferator-activated receptor modulators as potential chemopreventive agents.

Kopelovich L, Fay JR, Glazer RI, Crowell JA.

Mol Cancer Ther. 2002 Mar;1(5):357-63. Review. Erratum in: Mol Cancer Ther. 2002 May;1(7):564.

9.

Farnesyl protein transferase inhibitors as potential cancer chemopreventives.

Kelloff GJ, Lubet RA, Fay JR, Steele VE, Boone CW, Crowell JA, Sigman CC.

Cancer Epidemiol Biomarkers Prev. 1997 Apr;6(4):267-82. Review.

10.

Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventives.

Kelloff GJ, Fay JR, Steele VE, Lubet RA, Boone CW, Crowell JA, Sigman CC.

Cancer Epidemiol Biomarkers Prev. 1996 Aug;5(8):657-66. Review.

11.

Mechanistic considerations in the evaluation of chemopreventive data.

Kelloff GJ, Boone CW, Steele VE, Crowell JA, Lubet RA, Greenwald P, Hawk ET, Fay JR, Sigman CC.

IARC Sci Publ. 1996;(139):203-19. Review.

PMID:
8923032
12.

Mechanistic considerations in chemopreventive drug development.

Kelloff GJ, Boone CW, Steele VE, Fay JR, Lubet RA, Crowell JA, Sigman CC.

J Cell Biochem Suppl. 1994;20:1-24. Review.

PMID:
7616736
13.

Progress in applied chemoprevention research.

Kelloff GJ, Malone WF, Boone CW, Sigman CC, Fay JR.

Semin Oncol. 1990 Aug;17(4):438-55. Review. No abstract available.

PMID:
2143601
14.

Flavonoid inhibition of the human neutrophil NADPH-oxidase.

Tauber AI, Fay JR, Marletta MA.

Biochem Pharmacol. 1984 Apr 15;33(8):1367-9. No abstract available.

PMID:
6712740
15.

Radiolucent-radiopaque periapical lesions: a diagnostic challenge.

Wakefield CW, Fay JR, Eichel TF.

Gen Dent. 1983 Sep-Oct;31(5):406-8. No abstract available.

PMID:
6584384

Supplemental Content

Support Center